CBI’s Pharmaceutical Congress on Paragraph IV Disputes

September 3, 2008

Kurt R. Karst of Hyman, Phelps & McNamara, P.C. (and co-chief blogger of FDALawBlog.net) will be speaking at the Center for Business Intelligence’s Pharmaceutical Congress on Paragraph IV Disputes, October 15 – 16, 2008, at the Marriott Philadelphia Downtown in Philadelphia, Pennsylvania.  A copy of the program is available here.  At the event, preeminent members of the nation’s Food and Drug Bar will address a broad range of topics, including: 

  • FTC address on pharmaceutical antitrust
  • In depth analysis of recent court cases and their implications on brand and generic companies
  • Effects of KSR on brand and generic litigation strategies
  • Panel discussion on acceptable settlement strategies for paragraph IV disputes
  • Litigating paragraph IV disputes with multiple ANDA filers
  • Interpreting forfeiture provisions for better business decisions
  • Pre-suit preparedness strategies for paragraph IV disputes
  • Citizen petitions and their impact on generic entry
  • Declaratory judgments
  • At-risk launches

For more information or to register, please contact the Center for Business Intelligence toll-free by phone at 1-800-817-8601 or via e-mail at cbireg@cbinet.com.

Categories: Miscellaneous